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Blackwater fever is characterized by acute intravascu-
lar hemolysis with hemoglobinuria in patients with
Plasmodium falciparum malaria. Its pathogenesis and man-
agement are still debated. Nine cases of this syndrome
occurred in 2003 at Kiremba Hospital in Burundi in children
receiving multiple quinine treatments. 
B
lackwater fever (BWF) is a clinical entity well known
only in long-term residents in Plasmodium falci-
parum–endemic areas who take quinine irregularly. This
syndrome became less frequent when chloroquine was the
drug of choice for malaria from 1950 until the 1990s (1).
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is
also frequently associated with the syndrome; however, its
role is not determinant, as BWF is frequently described in
patients with normal erythrocyte G6PD levels who are
receiving quinine for severe malaria (2). Isolated cases
have also been described with other antimalarials, such as
halofantrine and mefloquine, which belong to the amino-
alcohol drug family (3–5).
The pathogenesis of BWF thus remains unclear (4,6,7).
Its management changed with the introduction of
artemisinin derivates but is still debated. White and other
researchers (2,8) state that parenteral quinine can be
stopped when artemisinin derivatives are available
because they seem to be safe and well tolerated. 
Clinical features defining BWF are well established
(2,9). The syndrome is characterized by severe intravascu-
lar hemolysis and anemia producing dark urine in patients
with severe malaria. Abdominal pain, jaundice,
hepatosplenomegaly, vomiting, and renal failure (especial-
ly in adults) have also been reported.
As P. falciparum resistance to chloroquine developed,
quinine was increasingly used in clinical practice for treat-
ing intermittent malaria infections. BWF seemed to reap-
pear at the end of the 1990s, according to descriptions in
several European clinics of imported diseases (3–5). It par-
ticularly affected European missionaries with years of pre-
vious residence in malarious areas. In fact, some of the
classical definitions of the syndrome described it in expa-
triate populations only (9). Cases of BWF in autochtho-
nous populations have recently been described in the liter-
ature from Southeast Asia (10) and in African children in
Senegal (7). We describe a large number of BWF cases in
the pediatric ward of a hospital in the Burundi highlands,
where no case has been observed in the previous 10-year
period (1992–2002). 
The Study
Since January 1992, a hospital-based survey of malaria
has been conducted at Kiremba Hospital in Ngozi
Province. This 140-bed facility is located 1,540 m above
sea level in the Burundi highlands; it serves a population
of 75,000 (11). 
For each case of malaria, laboratory data and clinical
findings are recorded. Rising illness and death rates are
being reported throughout Burundi, where P. falciparum
accounts for most cases (12). According to the Kiremba
Hospital registry, a 2-fold increase in admissions for
malaria in the pediatric ward (children <14 years of age)
was recorded from 1997 (658 cases) to 2002 (1,343 cases).
From February to December 2003, a period when 1,039
malaria patients were hospitalized, we observed 9 cases of
severe intravascular hemolysis with dark urine in pediatric
patients who had been treated with quinine. These children
were all male with a mean age of 8.2 years (range 3–14
years). According to patients’ health cards, all had been
previously treated with quinine, either parenterally or oral-
ly according to Burundi’s national policy for treating
severe malaria (10 mg/kg 3×/day for 7 days). Clinical and
laboratory data are presented in the Table. 
When BWF occurred, quinine was stopped and
artemether (3.2 mg/kg on day 1, then 1.6 mg/kg from day
2 to day 5), was administered intramuscularly in associa-
tion with 3 days of corticosteroid therapy. All patients had
severe anemia requiring blood transfusion according to
hospital policy (hemoglobin <4.5 g/dL or <6 g/dL with
accompanying dyspnea). Four patients needed l U of
blood; 5 other patients needed >1 U. No deaths were
recorded, and clinical outcome on discharge was satisfac-
tory: thick smears were negative and hemoglobin levels
had improved in all patients.
Conclusions
In Burundi, chloroquine was replaced by sulfadoxine-
pyrimethamine (SP) alone as firstline treatment for
uncomplicated malaria in 2001. However, the rapid devel-
opment of resistance to SP brought back the use of oral
quinine, a drug still available in health centers as well as in
hospital settings. Since November 2003, artesunate and
amodiaquine have replaced SP as firstline treatment in
Burundi (13).
The result of the new treatment guidelines was a con-
siderable reduction in the number of hospitalized malaria
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Spain cases in 2004 (671 cases from January 1 to October 31,
2004). No cases of BWF were observed in this period.
Despite changes in policy for the use of firstline antimalar-
ial drugs, however, parenteral quinine continued to be the
drug of choice for severe cases throughout this period. 
All 9 patients with BWF seen in 2003 (with 1 excep-
tion) lived in the area served by Kiremba Hospital and
were recorded during an 11-month period. This number
represents an incidence of 11.5 cases/100.000 population/
year.
In reviewing recent literature, we found only 1 publica-
tion on BWF involving an African population (7). The
study was carried out at the Dielmo village in Senegal,
where 3 cases were detected in a 10-year prospective study
in a small population (315 inhabitants). All 3 cases were in
children who suffered several malaria attacks and were
treated with oral or parenteral quinine, depending on the
severity of the case. As a consequence, quinine was with-
drawn as the drug of firstline therapy for uncomplicated
cases of malaria. No more cases of BWF were recorded
during the subsequent 6-year follow-up period.
In our study, patients were all boys admitted to the pedi-
atric ward. No cases of oligoanuria were seen, which is not
surprising in pediatric patients (14). At the onset of severe
intravascular hemolysis, the blood smears of 2 children
were negative for malaria; parasitemia was low in the oth-
ers. These findings agree with the definition of BWF as
being characterized by scanty or absent parasitemia
(4,6,9). We were unable to determine G6PD levels in our
patients, which is a major limitation of our study.
However, in view of the overlap between malaria, quinine
administration, and G6PD deficiency, the hemoglobinuria
triggered by this deficiency should not be seen as a sepa-
rate syndrome (10).
The management of our cases included 3 components:
First, treatment with parenteral (intramuscular) artemether
(3.2 mg/kg on day 1, then 1.6 mg/kg from days 2 to 5) after
stopping quinine, according to recent trends in the litera-
ture (3–5). Artemisinin derivates have not been implicated
in BWF episodes unless given in combination with meflo-
quine (8). Second, blood transfusion for severe anemia was
performed according to the above described hospital poli-
cy. And finally, a short course of corticosteroid therapy
was administered. 
Our experience suggests the need to review the defini-
tion of BWF since the syndrome affects not only adult
expatriates but also African children. All reported African
children with cases of BWF had frequently received oral
quinine therapy. African adults seem to be only occasion-
ally affected. This finding suggests that BWF occurs in
nonimmune persons or those who have not yet gained
immunity. This statement is supported by the lack of cases
in adults cured in the same hospital.
To reduce hemolysis, we treated BWF with corticos-
teroids, even though this step is not recommended by the
World Health Organization. Our reasoning was that the
phenomenon could be related to immune mechanisms in
quinine-sensitized erythrocytes (14).  
The influence of quinine seems to be an important fac-
tor in the pathogenesis of BWF. Other amino-alcohol
drugs such as mefloquine or halofantrine have never been
used intensively in Africa, principally because they are
expensive. When policy changes lead to less use of oral
quinine, BWF syndrome tends to disappear. Further simi-
lar reports from other areas in the African continent that
would confirm our findings could have important implica-
tions on national policies for treating malaria in African
children.
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